[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Download PDF
Table 1. 
Characteristics of the Studied Populationsa
Characteristics of the Studied Populationsa
Table 2. 
Prevalence of Histological Findingsa
Prevalence of Histological Findingsa
Table 3. 
Histological Findings in Relation to Ages at Endoscopy and Resection and Time Elapsed Since Surgery
Histological Findings in Relation to Ages at Endoscopy and Resection and Time Elapsed Since Surgery
Table 4. 
Prevalence of Histological Findings in Relation to HP Statusa
Prevalence of Histological Findings in Relation to HP Statusa
Table 5. 
Odds of GCPLs, Inflammation, and Activity in Helicobacter pylori –Positive Cases With Respect to Negative Cases
Odds of GCPLs, Inflammation, and Activity in Helicobacter pylori –Positive Cases With Respect to Negative Cases
1.
Dixon  MFGenta  RMYardley  JHCorrea  P Classification and grading of gastritis: the updated Sydney System: International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20 (10) 1161- 1181
PubMedArticle
2.
Correa  P Is gastric cancer preventable? Gut 2004;53 (9) 1217- 1219
PubMedArticle
3.
Correa  PHoughton  J Carcinogenesis of Helicobacter pyloriGastroenterology 2007;133 (2) 659- 672
PubMedArticle
4.
Correa  P A human model of gastric carcinogenesis. Cancer Res 1988;48 (13) 3554- 3560
PubMed
5.
Correa  P Bacterial infections as a cause of cancer. J Natl Cancer Inst 2003;95 (7) E3
PubMedArticle
6.
Matysiak-Budnik  TMégraud  F Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006;42 (6) 708- 716
PubMedArticle
7.
Caygill  CPHill  MJKirkham  JSNorthfield  TC Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet 1986;1 (8487) 929- 931
PubMedArticle
8.
Lundegårdh  GAdami  HOHelmick  CZack  MMeirik  O Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 1988;319 (4) 195- 200
PubMedArticle
9.
Onoda  NMaeda  KSawada  TWakasa  KArakawa  TChung  KH Prevalence of Helicobacter pylori infection in gastric remnant after distal gastrectomy for primary gastric cancer. Gastric Cancer 2001;4 (2) 87- 92
PubMedArticle
10.
Kaminishi  MShimizu  NYamaguchi  HHashimoto  MSakai  SOohara  T Different carcinogenesis in the gastric remnant after gastrectomy for gastric cancer. Cancer 1996;77 (8) (suppl)1646- 1653
PubMedArticle
11.
Safatle-Ribeiro  AVRibeiro Júnior  UReynolds  JC  et al.  Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. Cancer 1996;78 (11) 2288- 2299
PubMedArticle
12.
Bajtai  AHidvégi  J The role of gastric mucosal dysplasia in the development of gastric carcinoma. Pathol Oncol Res 1998;4 (4) 297- 300
PubMedArticle
13.
Giuliani  ASpada  SCorona  M  et al.  Cancer precursor lesions in intact stomach Helicobacter pylori gastritis and in resected stomach gastritis. J Exp Clin Cancer Res 2003;22 (3) 371- 378
PubMed
14.
Giuliani  ACaporale  ADemoro  M  et al.  Gastric cancer precursor lesions and Helicobacter pylori infection in patients with partial gastrectomy for peptic ulcer. World J Surg 2005;29 (9) 1127- 1130
PubMedArticle
15.
Correa  P Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52 (24) 6735- 6740
PubMed
16.
Goodwin  CSArmstrong  JAMarshall  BJ Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986;39 (4) 353- 365
PubMedArticle
17.
Rathbone  BJWyatt  JIHeatley  RV Campylobacter pyloridis: a new factor in peptic ulcer disease? Gut 1986;27 (6) 635- 641
PubMedArticle
18.
Dixon  MF Helicobacter pylori and peptic ulceration: histopathological aspects. J Gastroenterol Hepatol 1991;6 (2) 125- 130
PubMedArticle
19.
Sipponen  P Gastric cancer: a long-term consequence of Helicobacter pylori infection? Scand J Gastroenterol Suppl 1994;20124- 27
PubMedArticle
20.
Miehlke  SBayerdörffer  EMeining  AStolte  MMalfertheiner  P Identifying persons at risk for gastric cancer? Helicobacter 1997;2(suppl 1)S61- S66
PubMedArticle
21.
Shang  JPena  AS Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J Gastroenterol 2005;11 (27) 4131- 4139
PubMed
22.
Tersmette  ACGoodman  SNOfferhaus  GJ  et al.  Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients. Am J Epidemiol 1991;134 (1) 14- 21
PubMed
23.
Lu  CYKuo  CHLo  YC  et al.  The best method of detecting prior Helicobacter pylori infection. World J Gastroenterol 2005;11 (36) 5672- 5676
PubMed
24.
Urita  YMaeda  TIshihara  S  et al.  Endoscopic 13C-urea breath test for detection of Helicobacter pylori infection after partial gastrectomy. Hepatogastroenterology 2007;54 (78) 1891- 1894
PubMed
25.
Offerhaus  GJRieu  PNJansen  JBJoosten  HJLamers  CB Prospective comparative study of the influence of postoperative bile reflux on gastric mucosal histology and Campylobacter pylori infection. Gut 1989;30 (11) 1552- 1557
PubMedArticle
26.
Danesh  JAppleby  PPeto  R How often does surgery for peptic ulceration eradicate Helicobacter pylori? systematic review of 36 studies. BMJ 1998;316 (7133) 746- 747
PubMedArticle
27.
Safatle-Ribeiro  AVRibeiro  U  JrClarke  MR  et al.  Relationship between persistence of Helicobacter pylori and dysplasia, intestinal metaplasia, atrophy, inflammation, and cell proliferation following partial gastrectomy. Dig Dis Sci 1999;44 (2) 243- 252
PubMedArticle
28.
Abe  HMurakami  KSatoh  S  et al.  Influence of bile reflux and Helicobacter pylori infection on gastritis in the remnant gastric mucosa after distal gastrectomy. J Gastroenterol 2005;40 (6) 563- 569
PubMedArticle
29.
Pajares-Garcíia  JM Diagnosis of Helicobacter pylori: invasive methods. Ital J Gastroenterol Hepatol 1998;30(suppl 3)S320- S323
PubMed
30.
Alam  KSchubert  TTBologna  SDMa  CK Increased density of Helicobacter pylori on antral biopsy is associated with severity of acute and chronic inflammation and likelihood of duodenal ulceration. Am J Gastroenterol 1992;87 (4) 424- 428
PubMed
31.
Cohen  HLaine  L Endoscopic methods for the diagnosis of Helicobacter pyloriAliment Pharmacol Ther 1997;11(suppl 1)3- 9
PubMedArticle
32.
Howden  CWHunt  RHAd Hoc Committee on Practice Parameters of the American College of Gastroenterology, Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998;93 (12) 2330- 2338
PubMedArticle
33.
Bertoli Neto  JLLourenço  LGBertoli  CFUlbrich  FSSabbi  ARBueno  AG Evaluation of the efficacy of triple therapy regimen for Helicobacter pylori eradication in gastrectomized patients with gastric adenocarcinoma. Gastric Cancer 2006;9 (4) 291- 294
PubMedArticle
34.
O’Connor  HJDixon  MFWyatt  JI  et al.  Effect of duodenal ulcer surgery and enterogastric reflux on Campylobacter pyloridis. Lancet 1986;2 (8517) 1178- 1181
PubMedArticle
35.
Kato  TMotoyama  HAkiyama  N Helicobacter pylori infection in gastric remnant cancer after gastrectomy [in Japanese]. Nippon Rinsho 2003;61 (1) 30- 35
PubMed
36.
Fukuhara  KOsugi  HTakada  N  et al.  Duodenogastric reflux eradicates Helicobacter pylori after distal gastrectomy. Hepatogastroenterology 2004;51 (59) 1548- 1550
PubMed
37.
Kirsch  CMadisch  APiehler  PBayerdorffer  EStolte  MMiehlke  S Helicobacter pylori in gastric corpus of patients 20 years after partial gastric resection. World J Gastroenterol 2004;10 (17) 2557- 2559
PubMed
38.
Kato  SMatsukura  NTsukada  K  et al.  Helicobacter pylori infection–negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci 2007;98 (6) 790- 794
PubMedArticle
39.
Correa  PFontham  ETBravo  JC  et al.  Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti– Helicobacter pylori therapy. J Natl Cancer Inst 2000;92 (23) 1881- 1888
PubMedArticle
40.
Sung  JJLin  SRChing  JY  et al.  Atrophy and intestinal metaplasia one year after cure of H pylori infection: a prospective, randomized study. Gastroenterology 2000;119 (1) 7- 14
PubMedArticle
41.
Sugiyama  TSakaki  NKozawa  H  et al. H Pylori Forum Gastritis Study Group, Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther 2002;16(suppl 2)187- 190
PubMedArticle
42.
Sugiyama  T Development of gastric cancer associated with Helicobacter pylori infection. Cancer Chemother Pharmacol 2004;54(suppl 1)S12- S20
PubMed
43.
Mera  RFontham  ETBravo  LE  et al.  Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54 (11) 1536- 1540
PubMedArticle
44.
Ma  ZFWang  ZYZhang  JRGong  PChen  HL Carcinogenic potential of duodenal reflux juice from patients with long-standing postgastrectomy. World J Gastroenterol 2001;7 (3) 376- 380
PubMed
45.
Leung  WKLin  SRChing  JY  et al.  Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53 (9) 1244- 1249
PubMedArticle
46.
Weck  MNBrenner  H Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers Prev 2006;15 (6) 1083- 1094
PubMedArticle
47.
Weck  MNStegmaier  CRothenbacher  DBrenner  H Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther 2007;26 (6) 879- 887
PubMedArticle
48.
Hamaguchi  KOgawa  KKatsube  TKonno  SAiba  M Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication. Langenbecks Arch Surg 2004;389 (2) 83- 91
PubMedArticle
49.
Lam  SKTalley  NJ Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13 (1) 1- 12
PubMedArticle
50.
Malfertheiner  PMégraud  FO’Morain  C  et al. European Helicobacter Pylori Study Group (EHPSG), Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16 (2) 167- 180
PubMedArticle
51.
Meining  AMorgner  AMiehlke  SBayerdörffer  EStolte  M Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Best Pract Res Clin Gastroenterol 2001;15 (6) 983- 998
PubMedArticle
52.
Matsukura  NTajiri  TKato  S  et al.  Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy. Gastric Cancer 2003;6 (2) 100- 107
PubMed
Original Article
October 2010October 18, 2010

Screening of Helicobacter pylori Infection After Gastrectomy for Cancer or Peptic UlcerResults of a Cohort Study

Author Affiliations

Author Affiliations: Department of Surgery Pietro Valdoni, University of Rome La Sapienza, First Medical School (Drs Giuliani, Galati, Demoro, Scim[[ograve]], and Basso), and Department of Experimental Medicine and Pathology (Dr Pecorella), Policlinico Umberto I, Rome, Italy.

Arch Surg. 2010;145(10):962-967. doi:10.1001/archsurg.2010.211
Abstract

Background  Gastric cancer commonly follows a long-standing inflammation, mainly due to Helicobacter pylori (HP) infection. After resection, the stump develops precancerous alterations.

Design  Prospective study of patients undergoing endoscopy from April 1, 2000, through March 31, 2006.

Setting  University departments of Surgery and Experimental Medicine and Pathology.

Patients  One hundred eighty-seven patients receiving upper gastrointestinal tract endoscopy many years after surgery for duodenal ulcer or gastric cancer. Ten to 12 postoperative endoscopic biopsy samples were taken from the remnant stomach.

Main Outcome Measure  The risk of gastric cancer precursor lesions associated with HP infection.

Results  The gastric cancer precursor lesions were more common in the entire HP-positive population (odds ratio [OR], 2.37; 95% confidence interval [CI], 1.25-4.49; P = .007). However, HP-positive patients undergoing resection for cancer had a higher risk of the precursor lesions compared with HP-negative patients in the same diagnostic group (OR, 4.20; 95% CI, 1.10-15.96) and all patients undergoing resection for duodenal ulcer (OR, 1.59; 95% CI, 0.44-5.73).

Conclusion  The results of this investigation support the role of HP in gastric carcinogenesis and suggest that the HP eradication therapy might prevent the development of metachronous gastric cancer after gastric resection.

Cancer of the stomach is considered to develop from gastric cancer precursor lesions (GCPLs) such as chronic atrophic gastritis (CAG), intestinal metaplasia (IM), and dysplasia.13 Although a long-standing inflammation has always been considered mandatory in the development of gastric cancer, the exact mechanisms of carcinogenesis have remained unknown until the role of Helicobacter pylori (HP) infection in the process was first discovered,4,5 and several studies have later confirmed the link between HP infection and gastric cancer.6

The mucosa of the remaining gastric stump after resection for cancer or for peptic ulcer disease is considered prone to develop GCPLs and cancers79 because it is exposed to a new, nonphysiological environment and, probably, to HP.1012 We have previously dealt with the histological features related to HP status in intact and resected stomachs.13,14 The present study ascertains the prevalence of some histological features and of HP infection after gastric resection for peptic ulcer disease or gastric cancer, the primary outcome being the evaluation of the risk of GCPLs associated with HP infection.

METHODS

One hundred eighty-seven patients (138 were male and 49 were female) who had received gastric resection for peptic duodenal ulcer (group 1; n = 131) or advanced gastric cancer (group 2; n = 56) were included in this prospective study. All patients were asked for and granted their informed consent for inclusion. Reconstruction of the digestive tract consisted of a Billroth I gastroduodenostomy (n = 14) or a Billroth II gastrojejunostomy (n = 173). All 187 patients underwent upper digestive tract endoscopy between April 1, 2000, and March 31, 2006, at the endoscopic units of the departments of Surgery Pietro Valdoni and Medical Therapy of the University of Rome La Sapienza, First Medical School. All endoscopies were performed in the setting of postgastrectomy surveillance. None of these patients had received eradicating therapy for HP infection, antibiotics, nonsteroidal anti-inflammatory drugs, or chemotherapy in the 4 weeks before the diagnostic procedure. Endoscopic examination of the esophagus, gastric stump, anastomosis, and anastomosed small bowel for approximately 20 cm was routinely performed. A rapid urease test on gastric biopsy specimens from 37 cases, belonging to both groups, was performed at the beginning of the study. However, this test was later abandoned to reduce the number of total biopsy specimens because findings overlapped with the histological results in 36 of 37 cases. Histological microscopic examination was always performed. Most of the study patients had undergone the initial operation in other institutions and had not received any assessment of the HP status before our endoscopy. In any case, to the best of our knowledge, no patient had received any eradicating therapy after surgery. However, we prescribed antibiotic eradicating therapy to any patient we discovered to have positive findings for HP infection (HP positive), with no further HP status assessment at a later stage. Ten to 12 biopsy specimens were routinely taken from the stoma and the peristomal areas, from other areas of residual gastric mucosa along the lesser and greater curvatures, and from any areas showing erythema, erosion, or friability. Biopsy specimens were fixed in 10% formalin and embedded in paraffin. Sections were stained with hematoxylin-eosin. Additional sections of biopsy specimens were examined using Giemsa stain for HP detection. All histological slides were blindly reviewed by an experienced gastrointestinal pathologist (I.P.). The histological findings were classified as normal mucosa (NM; no changes in the mucosa), chronic nonatrophic gastritis (NAG; inflammatory cells in the lamina propria, but no loss of glands), CAG (loss of glands of any grade and stromal proliferation between the glands), IM (absorption, goblet, and Paneth cells in the superficial epithelium), and dysplasia (secretive, nuclear, and cytoplasmic abnormalities, excluding reactive, nondysplastic conditions). Helicobacter pylori infection, any histological mucosal changes, and inflammation1 (presence of chronic inflammatory cells in the lamina propria, such as lymphocytes, plasma cells, macrophages, and histiocytes) and its activity1 (presence of neutrophil granulocyte infiltration in the lamina propria or in intraepithelial foci) were recorded as present or absent. When more histological lesions were present, the case was classified according to increasing severity in the following order: NM, NAG, CAG, IM, and dysplasia. The last 3 (CAG, IM, and dysplasia) were all included in the GCPL group, which was the main focus of our study.

Statistical analysis was performed using the χ2 test, and P < .05 was considered significant. We also used the odds ratio (OR) with a 95% confidence interval (CI), defined as the ratio of the probability that an event (1 specific clinical or histological characteristic) would occur to the probability that it would not. Mean values are expressed as mean (SD). The study was approved by the ethics committee of the University of Rome La Sapienza, First Medical School.

RESULTS

The patients of both groups were divided for statistical analysis according to mean age at endoscopy, mean age at resection, and mean duration of postoperative period. Table 1 shows sex, age at digestive endoscopy (group 1 mean age, 69.6 [10.0] years; group 2, 69.2 [10.1] years), age at gastric resection (group 1 mean age, 40.8 [12.6] years; group 2, 60.8 [13.9] years), and time elapsed from surgery to endoscopy (group 1 mean interval, 27.8 [11.6] years; group 2, 7.6 [7.4] years). Male sex was prevalent in group 1 (OR, 3.18; 95% CI, 1.60-6.31; P = .001). In both groups, there was an even distribution in relation to age at endoscopy, age at resection, and duration of postoperative intervals. Group 2 showed a prevalence of NM (P = .02) and dysplasia, whereas in group 1 NAG, IM, inflammation (P = .003), activity (P < .001), and HP infection (P = .05) prevailed (Table 2).

GROUP 1

The biopsy specimens showed a prevailing incidence of NAG and dysplasia in older patients and IM in younger patients (P = .04) (Table 3). The patients undergoing operation at a younger age had an increased occurrence of NM and IM (P = .03), whereas those undergoing operation at an older age had a prevailing incidence of CAG and mononuclear cell infiltration. A longer postoperative period corresponded to an increased incidence of NM and dysplasia, whereas a shorter postoperative interval corresponded to an increased incidence of CAG, inflammation, and activity.

GROUP 2

Younger age at endoscopy was associated with a higher prevalence of IM, dysplasia, neutrophil granulocyte infiltration, and HP infection, whereas older age at endoscopy was associated with a higher rate of NAG, CAG, and inflammation. A prevalence of GCPLs was found in younger cases (OR, 1.54; 95% CI, 0.50-4.72) (Table 3).

Patients undergoing operation at an older age had more frequent NM, whereas those undergoing resection at a younger age presented with CAG, IM, dysplasia, neutrophil granulocyte infiltration, and HP infection. Patients undergoing resection at a younger age had more frequent findings of GCPLs (OR, 2.40; 95% CI, 0.76-7.60).

A shorter postoperative interval was related to prevalence of NM, with longer intervals related to prevalence of CAG, IM, inflammation, activity, and HP infection. The occurrence of GCPLs was related to longer postoperative intervals (OR, 1.91; 95% CI, 0.61-5.96).

INFLUENCE OF HP INFECTION

All HP-positive cases showed a higher prevalence of CAG (P = .02), IM (P = .09), inflammation (P < .001), and activity (P < .001), whereas HP-negative cases showed a prevalence of dysplasia. A prevalence of GCPLs was found in HP-positive cases (OR, 2.37; 95% CI, 1.25-4.49; P = .007) (Table 4).

The HP-negative cases in group 2 showed an increased occurrence of NM and dysplasia, whereas those of group 1 showed higher rates of IM (P = .06), inflammation (P = .03), and activity (P = .001).

The HP-positive cases in group 1 showed a nonsignificant increase of NAG and inflammation, whereas those in group 2 evidenced a higher risk of GCPLs (OR, 1.59; 95% CI, 0.44-5.73). The HP-positive cases in groups 1 and 2 showed an increased incidence of GCPLs, inflammation, and activity compared with HP-negative patients (Table 5).

COMMENT

To the best of our knowledge, this is the first study to compare mucosal lesions and HP status in the gastric stump after partial gastrectomy for duodenal ulcer and gastric cancer. It could be argued that it is difficult to compare gastric lesions in patients undergoing resection for benign and malignant illnesses because the mucosal baseline conditions are in many aspects different. Most gastric cancers arise from an atrophic and metaplastic mucosa,15 unlike peptic duodenal ulcer.1620 In addition, ages at resection and, therefore, duration of the postoperative follow-up are substantially different in the cases of benign or malignant conditions, because of a shorter likelihood of survival and follow-up time in the neoplastic population. In addition, although HP infection plays a critical role in malignancy and peptic ulcer disease, a number of other etiological factors are involved in gastric cancer.21 In any case, the residual mucosa in the gastric stump is considered at risk and precancerous as such, independent of indication for surgery.22 We determined HP status by means of conventional histological patterns, although more sensitive methods for detecting HP do exist,23,24 which could explain a higher prevalence of HP infection reported by others.9,2528 The maximal accuracy of histological analysis in detecting HP infection is obtained with a satisfactory number of biopsy specimens, optimal specimen processing, adequate staining, and an experienced observer.29 Our study fulfilled all these conditions. Theoretically, the patchy nature of HP infection might bias the results of biopsy-based histological studies; however, we have minimized this risk by taking 10 to 12 biopsy specimens. In addition, the use of 2 staining methods has reduced the likelihood of false-negative results.3033 Many factors render the mucosa of the gastric stump a progressively inhospitable environment for HP. Biliopancreatic reflux is regarded as the main cause of inhospitality to HP after gastric resection, and most of our patients received a Billroth II gastric resection, which particularly favors this reflux.26,3436

Patients in group 2 had undergone resection for advanced cancer; therefore, it is possible that, at surgery, the mucosa adjacent to the tumor had already become inhospitable to HP. In addition, although some patients in both groups may have undergone operation for an HP-negative condition such as duodenal ulcer caused by nonsteroidal anti-inflammatory drugs37 or gastric cancer developed without the promoter effect of HP infection,38 this could not be ascertained in our study, which did not investigate preoperative HP status.

Therefore, HP-positivity in our patients might indicate expression of a persistent or newly developed infection. In relation to mucosal alterations, we took into account their presence or absence, rather than their severity, to make the results easier to compare. There is a chance that some of the morphological changes of the residual mucosa were already present at surgery in relation to the causative disease and that, in the postoperative period, these lesions persisted, progressed, and/or even regressed in relation to HP status3943 and undefined other multiple factors.44 However, it was impossible for us to retrospectively ascertain the status of the gastric mucosa at the time of surgery. We observed that the prevalence of mucosal lesions in both groups was irregularly related to the time. Group 1 showed a higher risk for IM in younger patients at endoscopy and at gastric resection, whereas group 2 showed a higher risk for IM and dysplasia in the same cases. A longer postoperative period was related to an increased incidence of almost all mucosal lesions in group 2, whereas a longer postoperative period implied only an increased incidence of dysplasia in group 1. Other authors, however, have observed that time is an important factor ruling IM and CAG.43,4547

Lymphocyte and leukocyte infiltration of the lamina propria had a similar prevalence in the HP-positive cases of both groups, although there was a 4-fold risk of inflammation in group 1 compared with group 2 (Table 4). The HP-negative cases in group 1 showed a 2-fold and 4-fold risk of inflammation and activity, respectively, compared with HP-negative patients in group 2 (Table 4). These findings suggest that, apart from infection, environmental or lifestyle factors play a role in the development of some morphological changes.38,48

The resected stomach, because it is a precancerous condition, offers the unique opportunity to study the factors involved in gastric carcinogenesis. Our research considered some of these factors and showed no significant role of mucosal changes in relation to age (at endoscopy and at resection) and duration of postoperative period, although a longer postoperative period was related to more advanced lesions in group 2. In this study, however, the role of the disease leading to surgery on the residual mucosa lesions was evident. The prevalence of dysplasia in HP-positive patients was 4 times higher in group 2 compared with group 1, and HP-negative patients in group 2 presented a 2-fold risk of dysplasia compared with group 1 (Table 4). In addition, the role of infection was considerably significant. The risk of GCPLs, inflammation, and activity in HP-positive patients was notably increased compared with HP-negative patients (Table 5). This is the most significant finding of our study and proves that there is a link between HP infection and gastric carcinogenesis. Table 5 shows a wide range of 95% CIs for inflammation and activity, which suggests that more data should be collected to draw any conclusion in relation to the importance of HP positivity after gastric resection. However, the Asian and European guidelines strongly recommend HP eradication therapy after gastric resection,49,50 although it has been observed that therapy significantly decreases inflammation and activity, whereas glandular atrophy and IM persist unchanged.15,45,51,52 In any case, according to the results of our research, we strongly recommend HP status assessment and possible HP infection eradication therapy after gastric resection for malignant or benign disease.

CONCLUSIONS

The remnant mucosa after gastric resection for duodenal ulcer and gastric cancer is often a favorable environment for HP infection, which increases the risk of GCPLs, inflammation, and activity, in particular in patients who received surgery for gastric cancer. The eradication of HP infection from the gastric stump, therefore, may prevent the development of metachronous gastric cancer after partial gastrectomy. Given the relative ease of such an eradication, this should always be recommended after partial gastrectomy. The important question is, will eradicating the bacteria result in normalization of the reported histological abnormalities and reduce the risk of cancer in the gastric stump? In our opinion, it might, although we have no data to support this hypothesis, which, therefore, could be the basis for future research.

Back to top
Article Information

Correspondence: Luigi Basso, MD, Department of Surgery Pietro Valdoni, University of Rome Sapienza, First Medical School, Policlinico Umberto I, viale del Policlinico 155, 00161 Rome, Italy (luigi.basso@uniroma1.it).

Accepted for Publication: July 29, 2009.

Author Contributions:Study concept and design: Giuliani. Acquisition of data: Galati, Demoro, and Scimò. Analysis and interpretation of data: Pecorella and Basso. Drafting of the manuscript: Demoro and Scimò. Critical revision of the manuscript for important intellectual content: Giuliani, Galati, Pecorella, and Basso. Statistical analysis: Pecorella. Administrative, technical, and material support: Galati and Demoro. Study supervision: Giuliani and Basso.

Financial Disclosure: None reported.

References
1.
Dixon  MFGenta  RMYardley  JHCorrea  P Classification and grading of gastritis: the updated Sydney System: International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20 (10) 1161- 1181
PubMedArticle
2.
Correa  P Is gastric cancer preventable? Gut 2004;53 (9) 1217- 1219
PubMedArticle
3.
Correa  PHoughton  J Carcinogenesis of Helicobacter pyloriGastroenterology 2007;133 (2) 659- 672
PubMedArticle
4.
Correa  P A human model of gastric carcinogenesis. Cancer Res 1988;48 (13) 3554- 3560
PubMed
5.
Correa  P Bacterial infections as a cause of cancer. J Natl Cancer Inst 2003;95 (7) E3
PubMedArticle
6.
Matysiak-Budnik  TMégraud  F Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006;42 (6) 708- 716
PubMedArticle
7.
Caygill  CPHill  MJKirkham  JSNorthfield  TC Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet 1986;1 (8487) 929- 931
PubMedArticle
8.
Lundegårdh  GAdami  HOHelmick  CZack  MMeirik  O Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 1988;319 (4) 195- 200
PubMedArticle
9.
Onoda  NMaeda  KSawada  TWakasa  KArakawa  TChung  KH Prevalence of Helicobacter pylori infection in gastric remnant after distal gastrectomy for primary gastric cancer. Gastric Cancer 2001;4 (2) 87- 92
PubMedArticle
10.
Kaminishi  MShimizu  NYamaguchi  HHashimoto  MSakai  SOohara  T Different carcinogenesis in the gastric remnant after gastrectomy for gastric cancer. Cancer 1996;77 (8) (suppl)1646- 1653
PubMedArticle
11.
Safatle-Ribeiro  AVRibeiro Júnior  UReynolds  JC  et al.  Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. Cancer 1996;78 (11) 2288- 2299
PubMedArticle
12.
Bajtai  AHidvégi  J The role of gastric mucosal dysplasia in the development of gastric carcinoma. Pathol Oncol Res 1998;4 (4) 297- 300
PubMedArticle
13.
Giuliani  ASpada  SCorona  M  et al.  Cancer precursor lesions in intact stomach Helicobacter pylori gastritis and in resected stomach gastritis. J Exp Clin Cancer Res 2003;22 (3) 371- 378
PubMed
14.
Giuliani  ACaporale  ADemoro  M  et al.  Gastric cancer precursor lesions and Helicobacter pylori infection in patients with partial gastrectomy for peptic ulcer. World J Surg 2005;29 (9) 1127- 1130
PubMedArticle
15.
Correa  P Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52 (24) 6735- 6740
PubMed
16.
Goodwin  CSArmstrong  JAMarshall  BJ Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986;39 (4) 353- 365
PubMedArticle
17.
Rathbone  BJWyatt  JIHeatley  RV Campylobacter pyloridis: a new factor in peptic ulcer disease? Gut 1986;27 (6) 635- 641
PubMedArticle
18.
Dixon  MF Helicobacter pylori and peptic ulceration: histopathological aspects. J Gastroenterol Hepatol 1991;6 (2) 125- 130
PubMedArticle
19.
Sipponen  P Gastric cancer: a long-term consequence of Helicobacter pylori infection? Scand J Gastroenterol Suppl 1994;20124- 27
PubMedArticle
20.
Miehlke  SBayerdörffer  EMeining  AStolte  MMalfertheiner  P Identifying persons at risk for gastric cancer? Helicobacter 1997;2(suppl 1)S61- S66
PubMedArticle
21.
Shang  JPena  AS Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J Gastroenterol 2005;11 (27) 4131- 4139
PubMed
22.
Tersmette  ACGoodman  SNOfferhaus  GJ  et al.  Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients. Am J Epidemiol 1991;134 (1) 14- 21
PubMed
23.
Lu  CYKuo  CHLo  YC  et al.  The best method of detecting prior Helicobacter pylori infection. World J Gastroenterol 2005;11 (36) 5672- 5676
PubMed
24.
Urita  YMaeda  TIshihara  S  et al.  Endoscopic 13C-urea breath test for detection of Helicobacter pylori infection after partial gastrectomy. Hepatogastroenterology 2007;54 (78) 1891- 1894
PubMed
25.
Offerhaus  GJRieu  PNJansen  JBJoosten  HJLamers  CB Prospective comparative study of the influence of postoperative bile reflux on gastric mucosal histology and Campylobacter pylori infection. Gut 1989;30 (11) 1552- 1557
PubMedArticle
26.
Danesh  JAppleby  PPeto  R How often does surgery for peptic ulceration eradicate Helicobacter pylori? systematic review of 36 studies. BMJ 1998;316 (7133) 746- 747
PubMedArticle
27.
Safatle-Ribeiro  AVRibeiro  U  JrClarke  MR  et al.  Relationship between persistence of Helicobacter pylori and dysplasia, intestinal metaplasia, atrophy, inflammation, and cell proliferation following partial gastrectomy. Dig Dis Sci 1999;44 (2) 243- 252
PubMedArticle
28.
Abe  HMurakami  KSatoh  S  et al.  Influence of bile reflux and Helicobacter pylori infection on gastritis in the remnant gastric mucosa after distal gastrectomy. J Gastroenterol 2005;40 (6) 563- 569
PubMedArticle
29.
Pajares-Garcíia  JM Diagnosis of Helicobacter pylori: invasive methods. Ital J Gastroenterol Hepatol 1998;30(suppl 3)S320- S323
PubMed
30.
Alam  KSchubert  TTBologna  SDMa  CK Increased density of Helicobacter pylori on antral biopsy is associated with severity of acute and chronic inflammation and likelihood of duodenal ulceration. Am J Gastroenterol 1992;87 (4) 424- 428
PubMed
31.
Cohen  HLaine  L Endoscopic methods for the diagnosis of Helicobacter pyloriAliment Pharmacol Ther 1997;11(suppl 1)3- 9
PubMedArticle
32.
Howden  CWHunt  RHAd Hoc Committee on Practice Parameters of the American College of Gastroenterology, Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998;93 (12) 2330- 2338
PubMedArticle
33.
Bertoli Neto  JLLourenço  LGBertoli  CFUlbrich  FSSabbi  ARBueno  AG Evaluation of the efficacy of triple therapy regimen for Helicobacter pylori eradication in gastrectomized patients with gastric adenocarcinoma. Gastric Cancer 2006;9 (4) 291- 294
PubMedArticle
34.
O’Connor  HJDixon  MFWyatt  JI  et al.  Effect of duodenal ulcer surgery and enterogastric reflux on Campylobacter pyloridis. Lancet 1986;2 (8517) 1178- 1181
PubMedArticle
35.
Kato  TMotoyama  HAkiyama  N Helicobacter pylori infection in gastric remnant cancer after gastrectomy [in Japanese]. Nippon Rinsho 2003;61 (1) 30- 35
PubMed
36.
Fukuhara  KOsugi  HTakada  N  et al.  Duodenogastric reflux eradicates Helicobacter pylori after distal gastrectomy. Hepatogastroenterology 2004;51 (59) 1548- 1550
PubMed
37.
Kirsch  CMadisch  APiehler  PBayerdorffer  EStolte  MMiehlke  S Helicobacter pylori in gastric corpus of patients 20 years after partial gastric resection. World J Gastroenterol 2004;10 (17) 2557- 2559
PubMed
38.
Kato  SMatsukura  NTsukada  K  et al.  Helicobacter pylori infection–negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci 2007;98 (6) 790- 794
PubMedArticle
39.
Correa  PFontham  ETBravo  JC  et al.  Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti– Helicobacter pylori therapy. J Natl Cancer Inst 2000;92 (23) 1881- 1888
PubMedArticle
40.
Sung  JJLin  SRChing  JY  et al.  Atrophy and intestinal metaplasia one year after cure of H pylori infection: a prospective, randomized study. Gastroenterology 2000;119 (1) 7- 14
PubMedArticle
41.
Sugiyama  TSakaki  NKozawa  H  et al. H Pylori Forum Gastritis Study Group, Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther 2002;16(suppl 2)187- 190
PubMedArticle
42.
Sugiyama  T Development of gastric cancer associated with Helicobacter pylori infection. Cancer Chemother Pharmacol 2004;54(suppl 1)S12- S20
PubMed
43.
Mera  RFontham  ETBravo  LE  et al.  Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54 (11) 1536- 1540
PubMedArticle
44.
Ma  ZFWang  ZYZhang  JRGong  PChen  HL Carcinogenic potential of duodenal reflux juice from patients with long-standing postgastrectomy. World J Gastroenterol 2001;7 (3) 376- 380
PubMed
45.
Leung  WKLin  SRChing  JY  et al.  Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53 (9) 1244- 1249
PubMedArticle
46.
Weck  MNBrenner  H Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers Prev 2006;15 (6) 1083- 1094
PubMedArticle
47.
Weck  MNStegmaier  CRothenbacher  DBrenner  H Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther 2007;26 (6) 879- 887
PubMedArticle
48.
Hamaguchi  KOgawa  KKatsube  TKonno  SAiba  M Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication. Langenbecks Arch Surg 2004;389 (2) 83- 91
PubMedArticle
49.
Lam  SKTalley  NJ Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13 (1) 1- 12
PubMedArticle
50.
Malfertheiner  PMégraud  FO’Morain  C  et al. European Helicobacter Pylori Study Group (EHPSG), Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16 (2) 167- 180
PubMedArticle
51.
Meining  AMorgner  AMiehlke  SBayerdörffer  EStolte  M Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Best Pract Res Clin Gastroenterol 2001;15 (6) 983- 998
PubMedArticle
52.
Matsukura  NTajiri  TKato  S  et al.  Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy. Gastric Cancer 2003;6 (2) 100- 107
PubMed
×